泽璟制药(688266) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥43,725,271.60, with a net profit attributable to shareholders of ¥-119,438,902.55[6] - Total revenue for Q1 2022 was CNY 43,725,271.60, with no revenue reported in Q1 2021[31] - The net loss attributable to shareholders of the parent company was CNY -119,438,902.55 in Q1 2022, compared to CNY -79,712,996.47 in Q1 2021[34] - The total comprehensive loss for Q1 2022 was CNY -127,603,412.22, compared to CNY -83,954,230.10 in Q1 2021[34] - The net loss for Q1 2022 was -¥107,906,643.71, compared to a net loss of -¥76,407,616.71 in Q1 2021, indicating a worsening financial position[49] Research and Development - R&D investment totaled ¥121,273,151.53, representing an increase of 44.61% year-on-year, accounting for 277.35% of operating revenue[9] - The company has multiple innovative drugs in critical clinical trial phases, indicating ongoing R&D progress[15] - Research and development expenses for Q1 2022 reached ¥107,446,596.38, up from ¥76,021,890.21 in Q1 2021, reflecting a year-over-year increase of approximately 41.3%[46] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,689,373,448.41, a decrease of 3.24% from the end of the previous year[9] - Total liabilities increased to CNY 575,848,950.39 in the latest report from CNY 492,879,953.53 in the previous period[30] - The total assets of the company as of the reporting date were ¥1,599,458,149.33, a decrease from ¥1,645,093,055.30 in the previous year[46] - The total equity of the company decreased to ¥1,113,195,301.26 in Q1 2022 from ¥1,210,671,197.63 in Q1 2021, reflecting a decline of approximately 8%[46] Cash Flow - The net cash flow from operating activities was ¥-59,474,079.88, primarily due to increased R&D expenditures and market expansion costs[15] - The net cash flow from operating activities was -¥58,329,306.18, an improvement compared to -¥100,940,312.79 in the same quarter of the previous year[51] - Cash inflows from financing activities reached ¥121,000,000.00, compared to ¥30,300,000.00 in Q1 2021[53] - The ending balance of cash and cash equivalents was 1,121,674,220.87 CNY, down from 1,348,932,752.79 CNY year-over-year[41] Shareholder Information - The top shareholder, ZELIN SHENG, holds 20.80% of the shares, with a total of 49,909,607 shares[16] - The equity attributable to shareholders decreased by 10.62% to ¥1,068,822,286.40 compared to the end of the previous year[9] Inventory and Receivables - The company's inventory increased to CNY 64,180,122.89, up 23.6% from CNY 51,910,985.84[26] - The company reported accounts receivable of CNY 8,766,276.39, down significantly from CNY 62,370,697.78, indicating a decrease of 86.0%[22] Market Development - The company is in the early stages of commercialization, requiring significant investment in market development and academic promotion[15] - The company successfully launched a new drug, Tofacitinib, which was approved for sale in June 2021 and included in the National Medical Insurance Directory effective January 1, 2022[21]